

Formation of 1,2,4-oxadiazoles in the course of photooxidation of aromatic azides in acetonitrile

Ekaterina M. Chainikova, Marat F. Abdullin, Alexander N. Lobov, Aigul N. Teregulova and Rustam L. Safiullin

General information

NMR spectra were recorded in CDCl₃ or CD₃CN (Acros Organics, 99.95 atom % D) at 500 and 125 MHz for ¹H and ¹³C, respectively, on a Bruker Avance III 500 spectrometer using TMS as internal standard.

HPLC analysis was carried out on an YL9100 HPLC system.

Atmospheric pressure chemical ionization mass spectra (APCI-MS) were obtained on a HPLC mass-spectrometer LCMS-2010EV (Shimadzu) (direct syringe sample inlet, sample solution was in acetonitrile, mobile phase was MeCN/H₂O (95:5)) in positive and negative ions mode at the corona discharge needle ionizing electrode potential of 4.5 and -3.5 kV, respectively. The mobile phase flow rate was 0.1 ml min⁻¹. The nebulizer gas (nitrogen) flow rate was 1.5 dm min⁻¹. The temperature of the APCI interface, curved desolvation line and heater was 250°C, 230°C and 200°C, respectively.

High resolution mass spectra were recorded on a mass spectrometer MALDI-TOF Autoflex III (Bruker, Germany) with 2,5-dihydroxybenzoic acid as a matrix. Samples of compounds were prepared by “dried droplet” method (1:10).

Preparation of starting azides

Starting azides **1a–c** were synthesized from the corresponding anilines as described [P.A.S. Smith, J.H. Boyer, *Org. Synth.*, 1963, **4**, 75]. Phenyl azide (**1a**): ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 7.06 (d, 2H, ³J = 8.3, H-2(6)); 7.17 (t, 1H, ³J = 7.5, H-4); 7.38 (dd, 2H, ³J = 8.3, ³J = 7.5, H-3(5)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 119.99 (2CH, C2(6)); 125.99 (CH, C4); 130.91 (2CH, C3(5)); 141.02 (C, C1). ¹⁵N NMR (51 MHz, CD₃CN, TMS): δ (ppm) = 90.56 (N1'). 4-Chlorophenyl azide (**1b**): ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 7.04 (d, 2H, ³J = 8.6, H-2(6)); 7.37 (d, 2H, ³J = 8.6, H-3(5)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 121.62 (2CH, C2(6)); 130.67 (C, C4); 130.79 (2CH, C3(5)); 140.04 (C, C1). ¹⁵N NMR (51 MHz, CD₃CN, TMS): δ (ppm) = 90.29 (N1').

4-Bromophenyl azide (**1c**): ^1H NMR (500 MHz, CD_3CN , TMS): δ (ppm) = 6.99 (d, 2H, $^3J = 8.6$, H-2(6)); 7.51 (d, 2H, $^3J = 8.6$, H-3(5)). ^{13}C NMR (125 MHz, CD_3CN , TMS): δ (ppm) = 118.21 (C, C4); 122.01 (2CH, C2(6)); 133.76 (2CH, C3(5)); 140.58 (C, C1). ^{15}N NMR (51 MHz, CD_3CN , TMS): δ (ppm) = 90.49 (N1').

4-Methoxyphenyl azide (**1d**): ^1H NMR (500 MHz, CD_3CN , TMS): δ (ppm) = 3.76 (s, 3H, OMe); 6.93 (d, 2H, $^3J = 8.9$, H-3(5)); 6.99 (d, 2H, $^3J = 8.9$, H-2(6)). ^{13}C NMR (125 MHz, CD_3CN , TMS): δ (ppm) = 56.25 (CH_3 , OMe); 116.21 (2CH, C3(5)); 121.05 (2CH, C2(6)); 133.20 (C, C1); 158.22 (C, C4). ^{15}N NMR (51 MHz, CD_3CN , TMS): δ (ppm) = 87.37 (N1').

General procedure for the photooxidation of aryl azides

Solutions of azides **1a–c** in aerated acetonitrile were placed into glass flasks with ground-glass stoppers and irradiated by means of a 120 W Xe lamp through an NS-8 filter (>300 nm) at room temperature until the azide conversion reached $\sim 95\%$. The progress of the reaction was monitored by reverse-phase HPLC [analytical column: ProteCol C18 GP 125, 5 μ , 250 \times 4.6 mm; mobile phase: MeCN/ H_2O = 70:30 or 60:30]. Nitroso- and nitrobenzenes were identified by comparison with the authentic samples. At the end of the reaction, the solvent was removed from the reaction mixtures; the residue was dissolved in isopropanol (~ 0.5 ml) and separated by normal-phase HPLC [column: Kromasil 200 Si, 5 μ , 250 \times 10 mm (Dr. Maish GmbH; mobile phase: hexane/isopropanol = 85:15)].

Products of the photooxidation of azide 1a (16 mg, 0.134 mmol, 96% conv.). (4*E*)-5-(5-Methyl-1,2,4-oxadiazol-3-yl)penta-2,4-dienal (**2a**, 7 mg, 0.043 mmol, 32%); *cis*, *trans*-**2a**: ^1H NMR (500 MHz, CD_3CN , TMS): δ (ppm) = 2.61 (s, 3H, H(8)); 6.36 (ddt, $^3J_{2-1} = 7.8$ Hz, $^3J_{2-3} = 15.4$ Hz, $^4J_{2-4} = 0.8$ Hz, $^5J_{2-5} = 0.8$ Hz, 1H, H(2)); 6.67 (dt, $^3J_{5-4} = 11.5$ Hz, $^4J_{5-3} = 0.8$ Hz, $^5J_{2-5} = 0.8$ Hz, 1H, H(5)); 6.86 (td, $^3J_{4-3} = 11.5$ Hz, $^3J_{4-5} = 11.5$ Hz, $^4J_{4-2} = 0.8$ Hz, 1H, H(4)); 8.49 (ddd, $^3J_{3-2} = 15.4$ Hz, $^3J_{3-4} = 11.5$ Hz, $^4J_{3-5} = 0.8$ Hz, 1H, H(3)); 9.70 (d, $^3J_{1-2} = 7.8$, 1H, H(1)). ^{13}C NMR (125 MHz, CD_3CN , TMS): δ (ppm) = 12.62 (CH_3 , C(8)); 122.30 (CH, C(5)); 135.95 (CH, C(4)); 137.09 (CH, C(2)); 147.25 (CH, C(3)); 167.68 (C, C(6)); 178.25 (CC, (7)); 195.08 (CH, C(1)). *trans*, *trans*-**2a**: ^1H NMR (500 MHz, CD_3CN , TMS): δ (ppm) = 2.57 (s, 3H, H(8)); 6.41 (dd, $^3J_{2-3} = 14.9$ Hz, $^3J_{2-1} = 7.8$ Hz, 1H, H(2)); 7.03 (d, $^3J_{5-4} = 15.1$ Hz, 1H, H(5)); 7.40 (dd, $^3J_{3-2} = 14.9$ Hz, $^3J_{3-4} = 11.3$ Hz, 1H, H(3)); 7.48 (dd, $^3J_{4-5} = 15.1$ Hz, $^3J_{4-3} = 11.3$ Hz, 1H, H(4)); 9.65 (d, $^3J_{1-2} = 7.8$, 1H, H(1)). ^{13}C NMR (125 MHz, CD_3CN , TMS): δ (ppm) = 12.56 (CH_3 , C(8)); 125.77 (CH, C(5)); 136.27 (CH, C(2)); 136.62 (CH, C(4)); 149.87 (CH, C(3)); 168.02 (C, C(6)); 178.22 (C, C(7)); 194.81 (CH, C(1)). APCI-MS, *m/z* (relative intensity): 165(100) $[\text{M}+\text{H}]^+$, 164(100) $[\text{M}-\text{H}]^-$, 163(16) M^- . HR-MS (MALDI) calcd for $\text{C}_8\text{H}_9\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 165.0658. Found: 165.0664. PhNO_2 (1 mg, 0.008 mmol, 6%).

Products of the photooxidation of azide 1b (14 mg, 0.092 mmol, 96% conv.). (4E)-3-Chloro-5-(5-methyl-1,2,4-oxadiazol-3-yl)penta-2,4-dienal (**2b**, 7 mg, 0.035 mmol, 38%); *trans, cis-2b*: ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 2.59 (s, 3H, H(8)); 6.48 (dt, ³J₂₋₁ = 6.4 Hz, ⁴J₂₋₄ = 0.8 Hz, ⁵J₂₋₅ = 0.8 Hz, 1H, H(2)); 7.30 (dd, ³J₅₋₄ = 15.0 Hz, ⁵J₅₋₂ = 0.8 Hz, 1H, H(5)); 8.26 (dd, ³J₄₋₅ = 15.0 Hz, ⁴J₄₋₂ = 0.8 Hz, 1H, H(4)); 10.05 (d, ³J₁₋₂ = 6.4, 1H, H(1)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 12.60 (CH₃, C(8)); 125.24 (CH, C(5)); 130.78 (CH, C(4)); 131.70 (CH, C(2)); 147.06 (C, C(3)); 167.69 (C, C(6)); 178.57 (C, C(7)); 189.13 (CH, C(1)). *trans, trans-2b*: ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 2.58 (s, 3H, H(8)); 6.52 (dt, ³J₂₋₁ = 7.0 Hz, ⁴J₂₋₄ = 0.7 Hz, ⁵J₂₋₅ = 0.7 Hz, 1H, H(2)); 7.37 (dd, ³J₅₋₄ = 15.2 Hz, ⁵J₅₋₂ = 0.7 Hz, 1H, H(5)); 7.55 (dd, ³J₄₋₅ = 15.2 Hz, ⁴J₄₋₂ = 0.7 Hz, 1H, H(4)); 10.18 (d, ³J₁₋₂ = 6.4, 1H, H(1)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 12.57 (CH₃, C(8)); 123.76 (CH, C(5)); 130.90 (CH, C(2)); 135.86 (CH, C(4)); 147.45 (C, C(3)); 167.59 (C, C(6)); 178.51 (C, C(7)); 192.11 (CH, C(1)). APCI-MS, *m/z* (relative intensity): 199(69)/201(25) [M+H]⁺. HR-MS (MALDI) calcd for C₈H₇ClN₂O₂ [M]⁺: 198.0196/200.0161. Found: 198.0236/200.0198. 4-Chloronitrobenzene (1 mg, 0.006 mmol, 6%).

Products of the photooxidation of azide 1c (18 mg, 0.091 mmol, 95% conv.). (4E)-3-bromo-5-(5-methyl-1,2,4-oxadiazol-3-yl)penta-2,4-dienal (**2c**) (6 mg, 0.025 mmol, 27%); *trans, cis-2c*: ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 2.59 (s, 3H, H(8)); 6.75 (dt, ³J₂₋₁ = 6.1 Hz, ⁴J₂₋₄ = 0.8 Hz, ⁵J₂₋₅ = 0.8 Hz, 1H, H(2)); 7.23 (dd, ³J₅₋₄ = 15.0 Hz, ⁵J₅₋₂ = 0.8 Hz, 1H, H(5)); 8.19 (dd, ³J₄₋₅ = 15.0 Hz, ⁴J₄₋₂ = 0.8 Hz, 1H, H(4)); 9.98 (d, ³J₁₋₂ = 6.1, 1H, H(1)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 12.61 (CH₃, C(8)); 127.50 (CH, C(5)); 132.20 (CH, C(4)); 135.88 (CH, C(2)); 141.93 (C, C(3)); 167.55 (C, C(6)); 178.57 (C, C(7)); 188.90 (CH, C(1)). *trans, trans-2c*: ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 2.58 (s, 3H, H(8)); 6.74 (dt, ³J₂₋₁ = 6.8 Hz, ⁴J₂₋₄ = 0.7 Hz, ⁵J₂₋₅ = 0.7 Hz, 1H, H(2)); 7.35 (dd, ³J₅₋₄ = 15.2 Hz, ⁵J₅₋₂ = 0.7 Hz, 1H, H(5)); 7.53 (dd, ³J₄₋₅ = 15.2 Hz, ⁴J₄₋₂ = 0.7 Hz, 1H, H(4)); 10.07 (d, ³J₁₋₂ = 6.8, 1H, H(1)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 12.58 (CH₃, C(8)); 127.57 (CH, C(5)); 133.52 (CH, C(2)); 137.32 (CH, C(4)); 139.46 (C, C(3)); 167.60 (C, C(6)); 178.51 (C, C(7)); 194.23 (CH, C(1)). APCI-MS, *m/z* (relative intensity): 243(54)/245(65) (M+H)⁺. HR-MS (MALDI) calcd for C₈H₈BrN₂O₂ [M+H]⁺: 242.9764/244.9738. Found: 242.9719/244.9768. 4-Bromonitrobenzene (4 mg, 0.020 mmol, 22%).

Products of the photooxidation of azide 1d (15 mg, 0.101 mmol, 92% conv.). (2E,4E)-3-Methoxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)penta-2,4-dienal (*trans, cis-2d*, 9 mg, 0.046 mmol, 46%): ¹H NMR (500 MHz, CD₃CN, TMS): δ (ppm) = 2.58 (s, 3H, H(8)); 3.82 (s, 3H, H(9)); 5.63 (d, ³J₂₋₁ = 7.1 Hz, 1H, H(2)); 7.21 (d, 1H, ³J₅₋₄ = 15.5 Hz, H(5)); 7.95 (d, 1H, ³J₄₋₅ = 15.5 Hz, H(4)); 10.03 (d, ³J₁₋₂ = 7.1, 1H, H(1)). ¹³C NMR (125 MHz, CD₃CN, TMS): δ (ppm) = 12.61 (CH₃, C(8)); 57.14 (CH₃, C(9)); 108.12 (CH, C(2)); 121.50 (CH, C(5)); 128.89 (CH, C(4)); 167.96 (C, C(6)); 168.34 (C, C(3)); 178.30 (C, C(7)); 190.25 (CH, C(1)). APCI-MS, *m/z* (relative intensity): 195(100) [M+H]⁺. HR-MS

(MALDI) calcd for $C_9H_{11}N_2O_3$ $[M+H]^+$: 195.0764. Found: 195.0802. (5Z)-5-Hydroxyimino-2-isopropoxycyclopenta-1,3-diene-1-carbaldehyde (**4'**, 1 mg, 0.006 mmol, 6%): 1H NMR (500 MHz, CD_3CN , TMS): δ (ppm) = 1.42 (d, $^3J = 6.1$, 6H, H(8,9)); 4.99 (sept, $^3J = 6.1$, 1H, H(7)); 6.89 (d, $^3J_{4-5} = 5.9$ Hz, 1H, H(4)); 7.15 (d, $^3J_{5-4} = 5.9$ Hz, 1H, H(5)); 9.37 (s, 1H, H(6)); 13.63 (br.s. 1H, NOH). ^{13}C NMR (125 MHz, CD_3CN , TMS): δ (ppm) = 22.69 (2 CH_3 , C(8,9)); 78.79 (CH, C(7)); 106.90 (C, C(2)); 124.04 (CH, C(4)); 140.14 (CH, C(5)); 155.04 (C, C(1)); 181.89 (CH, C(6)); 183.18 (C, C(3)). APCI-MS, m/z (relative intensity): 182(40) $[M+H]^+$, 180(100) $[M-H]^-$. HR-MS (MALDI) calcd for $C_9H_{12}NO_3$ $[M+H]^+$: 182.0812. Found: 182.0771. 4-Methoxynitrobenzene (1 mg, 0.006 mmol, 6%).

HPLC chromatograms




Figure S1. Chromatogram of the reaction mixture obtained by photolysis of the azide **1a** solution (8.59×10^{-4} M) in aerated acetonitrile at room temperature. The mobile phase is MeCN/ H_2O = 60/40, detection at 300 and 310 nm. $t_R = 3.9$ min (nitrile oxide **Ba**); $t_R = 4.13$ and 4.50 min (isomeric forms of 1,2,4-oxadiazole **2a**); $t_R = 6.3$ min (nitrobenzene); $t_R = 6.9$ min (nitrosobezene); $t_R = 10.1$ min (azide **1a**). The reaction time – 1 hour (a), 1 day (b), 3 days (c).




Figure S2. Chromatogram of the reaction mixture obtained by photolysis of the azide **1b** solution (6.47×10^{-4} M) in aerated acetonitrile at room temperature. The mobile phase is MeCN/H₂O = 70/30, detection at 290 and 300 nm. $t_R = 4.0$ min (nitrile oxide **Bb**); $t_R = 4.7$ min (isomers of 1,2,4-oxadiazole **2b**); $t_R = 6.3$ min (4-chloronitrobenzene); $t_R = 7.2$ min (4-chloronitrosobenzene); $t_R = 9.5$ min (azide **1b**). The reaction time – 1 hour (a), 1 day (b), 4 days (c).




Figure S3. Chromatogram of the reaction mixture obtained by photolysis of the azide **1c** solution (6.13×10^{-4} M) in aerated acetonitrile at room temperature. The mobile phase is MeCN/H₂O = 70/30, detection at 290 and 300 nm. $t_R = 4.1$ min (nitrile oxide **Bc**); $t_R = 4.9$ min (isomers of 1,2,4-oxadiazole **2c**); $t_R = 6.7$ min (4-bromnitrobenzene); $t_R = 7.8$ min (4-bromnitrosobenzene); $t_R = 10.5$ min (azide **1c**). The reaction time – 1 hour (a), 1 day (b), 4 days (c).




Figure S4. Chromatogram of the reaction mixture obtained by photolysis of the azide **1d** solution (6.86×10^{-4} M) in aerated acetonitrile at room temperature. The mobile phase is MeCN/H₂O = 70/30, detection at 290 and 300 nm. $t_R = 3.35$ min (nitrile oxide **Bd**); $t_R = 3.5$ – 3.7 min (1,2,4-oxadiazole **2d** and cyclopetadiene **4d**); $t_R = 4.53$ min (4-methoxynitrosobenzene); $t_R = 4.97$ min (4-methoxynitrobenzene); $t_R = 6.7$ min (azide **1d**). The reaction time – 5 hours (a), 3 days (b).




Figure S6. Complete $^{13}\text{C}\{^1\text{H}\}$ spectrum of mixture *cis, trans-2a* and *trans, trans-2a* in CD_3CN .




Figure S7. DEPT editing ^{13}C NMR spectrum of mixture *cis, trans-2a* and *trans, trans-2a* in CD_3CN : a) $^{13}\text{C}\{^1\text{H}\}$ spectrum; b) DEPT-135; c) DEPT-90.




Figure S8. $\{^1\text{H}, ^{13}\text{C}\}$ HSQC spectrum of mixture *cis, trans-2a* and *trans, trans-2a* in CD_3CN .




Figure S9. $\{^1\text{H}, ^{13}\text{C}\}$ HMBC spectrum of mixture *cis, trans-2a* and *trans, trans-2a* in CD_3CN .




Figure S10. $\{^1\text{H}, ^1\text{H}\}$ COSY-DQF spectrum of mixture *cis, trans-2a* and *trans, trans-2a* in CD_3CN .





Figure S11. $\{^1\text{H}, ^1\text{H}\}$ NOESY spectrum of mixture *cis*, *trans*-**2a** and *trans*, *trans*-**2a** in CD_3CN .

NMR diagram of isomers of mixture *trans, cis-2b* and *trans, trans-2b* in CD₃CN. Chemical shifts (ppm), coupling constants (Hz) and significant {¹H, ¹³C} HMBC (solid arrow), {¹H, ¹H} COSY (dashed arrow) and NOESY (blue arrow) correlations.






Figure S12. Complete ^1H NMR spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN (top). Expanded ^1H NMR spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN (bottom).




Figure S13. Complete $^{13}\text{C}\{^1\text{H}\}$ spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN .




Figure S14. DEPT editing ^{13}C NMR spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN : a) $^{13}\text{C}\{^1\text{H}\}$ spectrum; b) DEPT-135; c) DEPT-90.




Figure S15. $\{^1\text{H}, ^{13}\text{C}\}$ HSQC spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN .




Figure S16. $\{^1\text{H}, ^{13}\text{C}\}$ HMBC spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN .




Figure S17. $\{^1\text{H}, ^1\text{H}\}$ COSY spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN .





Figure S18. $\{^1\text{H}, ^1\text{H}\}$ NOESY spectrum of mixture *trans, cis-2b* and *trans, trans-2b* in CD_3CN .

NMR diagram of isomers of mixture *trans, cis-2c* and *trans, trans-2c* in CD₃CN. Chemical shifts (ppm), coupling constants (Hz) and significant {¹H, ¹³C} HMBC (solid arrow), {¹H, ¹H} COSY (dashed arrow) and NOESY (blue arrow) correlations.






Figure S19. Complete ¹H NMR spectrum of mixture *trans, cis*-**2c** and *trans, trans*-**2c** in CD₃CN (top). Expanded ¹H NMR spectrum of mixture *trans, cis*-**2c** and *trans, trans*-**2c** in CD₃CN (bottom).




Figure S20. Complete $^{13}\text{C}\{^1\text{H}\}$ spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN .




Figure S21. DEPT editing ^{13}C NMR spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN : a) $^{13}\text{C}\{^1\text{H}\}$ spectrum; b) DEPT-135; c) DEPT-90.




Figure S22. $\{^1\text{H}, ^{13}\text{C}\}$ HSQC spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN .




Figure S23. $\{^1\text{H}, ^{13}\text{C}\}$ HMBC spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN .




Figure S24. $\{^1\text{H}, ^1\text{H}\}$ COSY spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN .





Figure S25. $\{^1\text{H}, ^1\text{H}\}$ NOESY spectrum of mixture *trans, cis-2c* and *trans, trans-2c* in CD_3CN .

NMR diagram of isomers of mixture *trans*, *cis*-**2d** and **4'** in CD₃CN. Chemical shifts (ppm), coupling constants (Hz) and significant {¹H, ¹³C}, {¹H, ¹⁵N} HMBC (solid arrow), {¹H, ¹H} COSY (dashed arrow) and NOESY (blue arrow) correlations.






Figure S26. Complete ^1H NMR spectrum of mixture *trans, cis-2d* and **4'** in CD_3CN (top).

Expanded ^1H NMR spectrum mixture *trans, cis-2d* and **4'** in CD_3CN (bottom).




Figure S27. Complete $^{13}\text{C}\{^1\text{H}\}$ spectrum of mixture *trans, cis-2d* and **4'** in CD_3CN .




Figure S28. DEPT editing ^{13}C NMR spectrum of mixture *trans, cis-2d* and **4'** in CD_3CN : a) $^{13}\text{C}\{^1\text{H}\}$ spectrum; b) DEPT-135; c) DEPT-90.




Figure S29. $\{^1\text{H}, ^{13}\text{C}\}$ HSQC spectrum of mixture *trans, cis*-**2d** and **4'** in CD_3CN .




Figure S30. $\{^1\text{H}, ^{13}\text{C}\}$ HMBC spectrum of mixture *trans, cis*-**2d** and **4'** in CD_3CN .




Figure S31. $\{^1\text{H}, ^1\text{H}\}$ COSY spectrum of mixture *trans*, *cis*-**2d** and **4'** in CD_3CN .




Figure S32. $\{^1\text{H}, ^1\text{H}\}$ NOESY spectrum of mixture *trans, cis*-**2d** and **4'** in CD₃CN.

High resolution mass spectra




Figure S33. Positive ion MALDI mass spectrum of **2a**.




Figure S34. Positive ion MALDI mass spectrum of **2d** (m/z 195.0802), **4'** (m/z 182.0771).




Figure S35. Positive ion MALDI mass spectrum of **2b**.




Figure S36. Positive ion MALDI mass spectrum of **2c**.

APCI-MS data




Figure S37. Positive ion APCI mass spectrum of **2a**.




Figure S38. Negative ion APCI mass spectrum of **2a**.




Figure S39. Positive ion APCI mass spectrum of **2d** (m/z 195), **4'** (m/z 182).




Figure S40. Negative ion APCI mass spectrum of **4'**.




Figure S41. Positive ion APCI mass spectrum of **2b**.




Figure S42. Positive ion APCI mass spectrum of **2c**.